drugset / Trial / NCT06260163

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

NCT06260163

Phase 3 Active not recruiting 112 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of guselkumab in pediatric participants with moderately to severely active ulcerative colitis at the end of maintenance therapy among participants who were induction responders.

Timeline

Start
2024-01-19
Primary completion
2027-02-10
Completion
2027-04-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Guselkumab Monoclonal antibody Subcutaneous

Indications